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Timing of initiation of antiretroviral therapy in AIDS-free 
HIV-1-infected patients: a collaborative analysis of 18 HIV 
cohort studies
When To Start Consortium*
Summary
Background The CD4 cell count at which combination antiretroviral therapy should be started is a central, unresolved 
issue in the care of HIV-1-infected patients. In the absence of randomised trials, we examined this question in 
prospective cohort studies.
Methods We analysed data from 18 cohort studies of patients with HIV. Antiretroviral-naive patients from 15 of these 
studies were eligible for inclusion if they had started combination antiretroviral therapy (while AIDS-free, with a 
CD4 cell count less than 550 cells per μL, and with no history of injecting drug use) on or after Jan 1, 1998. We used 
data from patients followed up in seven of the cohorts in the era before the introduction of combination therapy 
(1989–95) to estimate distributions of lead times (from the ﬁ rst CD4 cell count measurement in an upper range to the 
upper threshold of a lower range) and unseen AIDS and death events (occurring before the upper threshold of a lower 
CD4 cell count range is reached) in the absence of treatment. These estimations were used to impute completed 
datasets in which lead times and unseen AIDS and death events were added to data for treated patients in deferred 
therapy groups. We compared the eﬀ ect of deferred initiation of combination therapy with immediate initiation on 
rates of AIDS and death, and on death alone, in adjacent CD4 cell count ranges of width 100 cells per μL.
Findings Data were obtained for 21 247 patients who were followed up during the era before the introduction of 
combination therapy and 24 444 patients who were followed up from the start of treatment. Deferring combination 
therapy until a CD4 cell count of 251–350 cells per μL was associated with higher rates of AIDS and death than 
starting therapy in the range 351–450 cells per μL (hazard ratio [HR] 1·28, 95% CI 1·04–1·57). The adverse eﬀ ect of 
deferring treatment increased with decreasing CD4 cell count threshold. Deferred initiation of combination therapy 
was also associated with higher mortality rates, although eﬀ ects on mortality were less marked than eﬀ ects on AIDS 
and death (HR 1·13, 0·80–1·60, for deferred initiation of treatment at CD4 cell count 251–350 cells per μL compared 
with initiation at 351–450 cells per μL).
Interpretation Our results suggest that 350 cells per μL should be the minimum threshold for initiation of antiretroviral 
therapy, and should help to guide physicians and patients in deciding when to start treatment.
Funding UK Medical Research Council.
Introduction
Combination antiretroviral therapy has substantially 
reduced morbidity and mortality in HIV-1-infected 
individuals since its introduction in 1996.1,2 Short-term 
randomised controlled trials in immunodeﬁ cient patients 
showed that rates of AIDS or death were halved after 
approximately 1 year of combination therapy compared 
with rates in patients treated with drugs from only one 
antiretroviral drug class.3 The clinical eﬀ ect of 
combination therapy has not been examined in a long-
term trial, but observational data suggest that this 
treatment reduces rates of AIDS or death over several 
years, both in immunodeﬁ cient patients and in those 
with high CD4 cell counts.4,5
A central, unresolved issue is the CD4 cell count at 
which combination antiretroviral therapy should be 
started in patients who have not yet had an AIDS-
deﬁ ning event. The best way to address this question is 
to randomise AIDS-free HIV-1-infected patients to 
treatment with combination therapy that is either started 
when the CD4 cell count is in an upper range or deferred 
until the upper threshold of a lower CD4 cell count 
range is reached. So far, no such randomised controlled 
trial has been done: the evidence is limited to a sub-
study in the Strategies for Management of Antiretroviral 
Therapy (SMART) trial,6 which suggested that compared 
with initiation of treatment at a CD4 cell count of more 
than 350 cells per μL, delayed initiation until the 
CD4 cell count was less than 250 cells per μL more than 
tripled the rate of AIDS or death and, unexpectedly, 
increased the rate of other serious adverse events.7 
In the absence of evidence from randomised trials, the 
question of when to start combination therapy is best 
addressed in prospective observational studies of HIV-1-
infected individuals. Most analyses of such data have 
compared rates of AIDS and death from the time that 
patients started treatment8–10 (ﬁ gure 1A). However, such 
comparisons are problematic because they do not account 
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for AIDS events or deaths that occur during the so-called 
lead time, before the upper threshold of the lower CD4 cell 
count range is reached (ﬁ gure 1B). These unseen events, 
as well as lead times, will be ignored in analyses where 
patients’ follow-up time is measured from the start of 
treatment, which introduces lead-time bias.11,12
We undertook a collaborative analysis of data from 
cohort studies to estimate the eﬀ ect of initiation of 
combination antiretroviral therapy in diﬀ erent CD4 cell 
count ranges.
Methods
Patients and procedures
We used data from seven cohort studies with patients 
followed up during the era before the introduction of 
combination antiretroviral therapy, and data from the 
Antiretroviral Therapy (ART) Cohort Collaboration of 
patients followed up from the start of treatment, to 
estimate rates of AIDS or death in patients starting 
treatment in diﬀ erent CD4 cell count ranges, taking into 
account the probability of progression to AIDS or death 
before the upper threshold of the lower CD4 cell count 
range is reached. Patients whose presumed HIV 
transmission was by injecting drug use were analysed 
separately, because they have a high prevalence of 
comorbidities such as chronic hepatitis C13 and worse 
prognosis on combination therapy.14,15
Analyses of progression before starting combination 
therapy included patients followed before the 
introduction of this treatment (July 1, 1989, to 
Dec 31, 1995). We included patients with a CD4 cell 
count in the range 0 cells per μL to 550 cells per μL 
from the following seven cohort studies: the Multicenter 
AIDS Cohort Study (MACS),16 the Swiss HIV Cohort 
Study (SHCS),17 the ANRS CO4 French Hospital 
Database on HIV (FHDH),18 the ANRS CO3 Aquitaine 
Cohort,19 the Amsterdam Cohort Studies,20 the South 
Alberta Clinic,21 and the Concerted Action on 
Seroconversion to AIDS and Death in Europe 
(CASCADE) collaboration (excluding patients who were 
also included in the other cohorts).22 Patients had 
CD4 cell count measurements taken at scheduled 
clinics and were followed up for clinical AIDS events 
and death. A small number of patients who started 
combination therapy before Jan 1, 1996, were excluded. 
Analyses of progression after the start of combination 
therapy included all patients enrolled in one of 15 cohorts 
participating in the ART Cohort Collaboration who 
started treatment on or after Jan 1, 1998, with a CD4 cell 
count between 0 cells per μL and 550 cells per μL. We 
excluded patients if they had an AIDS diagnosis before 
starting combination therapy. The ART Cohort 
Collaboration includes cohort studies from Europe and 
North America, and was established with the aim of 
describing the prognosis of antiretroviral-naive patients 
starting combination therapy. The study design has been 
described in detail elsewhere.10,23,24 Prospective cohort 
studies were eligible for inclusion in the ART Cohort 
Collaboration if they had enrolled at least 
100 HIV-1-infected patients aged 16 years or older who 
had not previously received antiretroviral therapy and 
who had started treatment with a combination of at least 
three drugs, including nucleoside reverse transcriptase 
inhibitors, protease inhibitors, or non-nucleoside reverse 
transcriptase inhibitors, with a median duration of 
follow-up of at least 1 year. All cohorts provided 
anonymised data on a predeﬁ ned set of demographic, 
laboratory, and clinical variables. 
The 15 cohorts from the ART Cohort Collaboration 
that contributed data for this analysis included four 
previously mentioned cohorts17–19,21 as well as the AIDS 
Therapy Evaluation Netherlands project (ATHENA),25 
the Italian Cohort of Antiretroviral-Naive Patients 
(ICONA),26 the Frankfurt HIV Cohort,27 the Köln-Bonn 
Cohort,28 the Collaborations in HIV Outcomes Research 
United States (CHORUS),29 the 1917 Clinic Cohort 
University of Birmingham, Alabama,30 the Veterans 
Aging Cohort Study (VACS),31 the London Royal Free 
Hospital Cohort,32 the British Columbia Centre for 
Excellence in HIV/AIDS,33 the Proyecto para la Informa-
tizacion del Seguimiento Clinico epidemiologico de los 
pacientes con Infección por VIH/SIDA (PISCIS),34 and 
the EuroSIDA study, which obtains data from 20 coun-
tries in Europe and Argentina (excluding patients who 
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Figure 1: Comparison of analyses from (A) initiation of treatment and 
(B) time of ﬁ rst CD4 cell count measurement in the upper range
For more on the ART Cohort 
Collaboration see http://www.
art-cohort-collaboration.org
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were also included in other ART Cohort Collaboration 
cohorts).35 Contributors to each cohort are listed in the 
webappendix (pp 1–8).
Statistical analysis
Data for patients who remained alive were censored at 
the patient’s last visit, plus 50% of the mean time 
between visits for each cohort. For example, if a cohort 
had a mean of 6 months between follow-up visits, data 
were censored at the patient’s last visit plus 3 months. 
Patients with a gap of more than 1 year between clinic 
visits were deemed lost to follow-up and their data were 
censored at the beginning of the gap plus 50% of the 
mean time between visits. Follow-up of patients in the 
era before the introduction of combination antiretroviral 
therapy was administratively censored on Dec 31, 1995, 
and, in patients starting treatment, at 6 years after 
initiation of treatment or at the (cohort-speciﬁ c) date of 
the close of the database. 
We used data for patients receiving combination therapy 
to derive Kaplan-Meier estimates of cumulative 
probabilities of progression to AIDS and death from the 
time of treatment initiation, according to CD4 cell count at 
initiation. We used Cox regression to estimate naive 
hazard ratios (HRs) for AIDS or death (ie, HRs based on 
analyses that ignored lead time and unseen AIDS and 
death events) that compared individuals in diﬀ erent 
CD4 cell count categories at the start of treatment. In 
sensitivity analyses, we examined whether adjustment for 
patient characteristics at the time of treatment initiation 
altered these naive HRs. 
To account for lead time and unseen AIDS and death 
events, we used a method described by Cole and 
colleagues,12 in which missing data on lead time and 
unseen events in the deferred initiation group are 
recovered by use of multiple imputation.36 Full details are 
given in the webappendix (p 9). We used data from before 
the introduction of combination therapy to model the 
distribution of times from the ﬁ rst CD4 cell count 
measurement in the upper CD4 cell count range to the 
upper threshold of the lower CD4 cell count range (ie, 
lead time) and the probability of progression to AIDS or 
death before reaching the upper threshold of the lower 
CD4 cell count range (ie, unseen events; webappendix 
p 10). We repeated all comparisons with death alone as 
the endpoint, assuming that combination therapy has no 
eﬀ ect on deaths for 2 weeks and that an AIDS diagnosis 
will lead to immediate initiation of treatment. Therefore, 
in patients receiving combination therapy, deaths within 
2 weeks of initiation were excluded, whereas in data from 
the era before combination therapy, deaths included in 
analyses were those before the upper threshold of the 
lower CD4 cell count range was reached, or within 
2 weeks of an AIDS diagnosis. We examined whether 
progression rates diﬀ ered between the earlier (1989–91) 
and later (1992–95) years of the era before combination 
therapy, by separating follow-up time and including 
interaction terms in Cox regression models. We used 
random-eﬀ ects regression models for log-transformed 
CD4 cell counts to estimate the median decline in CD4 
cell counts during the era before combination therapy.
On the basis of the ﬁ tted distributions, imputation was 
used to create completed datasets, in which lead times 
and unseen AIDS and death events were added to the 
data for combination therapy, for patients in the deferred 
initiation group. We used Cox regression to estimate 
HRs that compared deferred with immediate initiation 
of treatment for each completed dataset, then combined 
these by use of Rubin’s formula.36 We used generalised 
gamma distributions for the lead times and unseen 
events, after redistributing patients with censored data 
according to the proportions of patients that progressed 
to AIDS or death and that reached the upper threshold of 
the lower CD4 cell count range to estimate the probability 
Patients followed up in the era 
before combination 
antiretroviral therapy 
(n=21 247)
Patients receiving 
combination 
antiretroviral therapy 
(n=24 444)
Age (years) 34 (28–41) 37 (31–45)
Female 4813 (23%) 7154 (29%)
CD4 cell count (cells per μL) 354 (264–448) 230 (130–330)
Log₁₀ HIV-1 RNA NA 4·9 (4·4–5·3)
Transmission group*
Heterosexual sex 6961 (33%) 11 382 (51%)
Men who have sex with men 11 874 (56%) 8483 (38%)
Other/unknown 2412 (11%) 2485 (11%)
Year of enrolment
1989–90 5784 (27%) ··
1991–92 6586 (31%) ··
1993–95 8877 (42%) ··
1998–99 ·· 7000 (29%)
2000–02 ·· 9490 (39%)
2003–06 ·· 7954 (33%)
Initial combination antiretroviral therapy regimen
Protease inhibitor-based triple regimen ·· 116 44 (48%)
NNRTI-based triple regimen ·· 8696 (36%)
NRTI only ·· 2347 (10%)
Other† ·· 1757 (7%)
AIDS and death during follow-up
Total follow-up (years) 68 253 81 071
Length of follow-up (years) 3·1 (1·9–4·5) 3·2 (1·5–5·3)
Development of AIDS 5356 (25%) 1860 (8%)
Deaths 3630 (17%) 808 (3%)
AIDS or death 5893 (28%) 2366 (10%)
NA=not available. NNRTI=non-nucleoside reverse transcriptase inhibitor. NRTI=nucleoside reverse transcriptase 
inhibitor. Data are n (%) or median (IQR). Baseline is date of start of follow-up in the era before combination 
antiretroviral therapy, and date of start of treatment for patients receiving combination therapy. *Excluding 
2064 patients from the Veterans Aging Cohort Study,31 in whom transmission group was classiﬁ ed only as injecting 
drug use or other. †Non-standard regimen consisting of more than one protease inhibitor and/or NNRTI, or more than 
three drugs (excluding ritonavir-boosting of protease inhibitors).
Table 1: Characteristics at baseline and events recorded during follow-up for patients in the era before 
the introduction of combination antiretroviral therapy and for patients receiving combination therapy
See Online for webappendix
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of progression before reaching the threshold. We 
examined the proportional hazards assumption by 
comparing progression rates in the ﬁ rst 2 years with 
rates from 2 years to the end of follow-up (6 years).
We compared deferred with immediate initiation of 
combination therapy in adjacent ranges of width 
100 cells per μL. We started with a comparison of 
initiation at 101–200 cells per μL compared with 
deferred initiation at 0–100 cells per μL, then compared 
initiation at 126–225 cells per μL with deferred initiation 
at 26–125 cells per μL and, by use of successive 
increments of 25 cells per μL, made similar comparisons 
up to initiation at 451–550 cells per μL with deferred 
initiation at 351–450 cells per μL. We undertook 
sensitivity analyses restricted to patients included in 
four cohorts that provided both data for patients in the 
era before combination therapy and data for patients 
receiving combination therapy (ANRS CO4 FHDH,18 
ANRS CO3 Aquitaine Cohort,19 Swiss HIV Cohort 
Study,17 and the South Alberta Clinic Cohort21). We also 
A
0
5
10
15
20
25
30
35
40
0 1 2 3 4 5 6
0–50
51–150
151–250
251–350
351–450
451–550
0–50 cells per μL
51–150 cells per μL
151–250 cells per μL
251–350 cells per μL
351–450 cells per μL
451–550 cells per μL
Time from start of combination antiretroviral therapy (years)
Time from start of combination antiretroviral therapy (years)
Pr
ob
ab
ili
ty
 o
f A
ID
S 
or
 d
ea
th
 (%
)
Number at risk
2594 1800 1417 1091 784 512 300
4638 3607 2875 2184 1570 1038 597
6406 4963 3763 2766 1957 1279 763
5753 4565 3570 2760 2058 1444 861
3260 2719 2315 1855 1492 1095 681
1793 1529 1326 1108 899 684 437
CD4 cell count range (cells per μL)
Pr
ob
ab
ili
ty
 o
f d
ea
th
 (%
)
5
10
15
0
0 1 2 3 4 5 6
2594
4638
6406
5753
3260
1793
2230
3919
5177
4707
2793
1576
1842
3215
4029
3756
2413
1384
1465
2516
3005
2947
1965
1182
1077
1856
2163
2238
1604
976
728
1227
1439
1576
1188
744
419
718
860
943
740
479
0–50 cells per μL
51–150 cells per μL
151–250 cells per μL
251–350 cells per μL
351–450 cells per μL
451–550 cells per μL
Number at risk
AB
Figure 2: Cumulative probability of (A) AIDS or death or (B) death alone after initiation of combination antiretroviral therapy, according to range of CD4 cell 
count at the time of treatment initiation
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undertook further sensitivity analyses in which 
distributions of lead times and unseen events were 
estimated on the assumption that treatment in the 
deferred initiation group was started at the ﬁ rst CD4 
cell count measurement in the lower range or, if there 
was no such measurement, at the midpoint of the 
range. We also plotted HRs for the cumulative eﬀ ects of 
delayed initiation compared with initiation in the range 
Higher CD4 cell 
count range 
(cells per μL)
Lower CD4 cell 
count range (cells 
per μL)
Data for 1989–95* Data for patients on combination 
antiretroviral therapy
Hazard ratio (95% CI) for AIDS or 
death
Number of 
patients in 
higher CD4 cell 
count range
Estimated 
median 
lead time 
(years)†
Estimated proportion of patients 
progressing to AIDS/death before 
reaching upper threshold of lower 
CD4 cell count range (% [95% CI])
Number of 
patients
Number of 
AIDS/
death 
events
Estimated 
number 
of unseen 
events
Naive‡ Adjusted for lead 
times and unseen 
events
451–550 351–450 5015 0·67 1·6% (1·1–2·1) 5047 260 53 1·04 (0·81–1·34) 0·99 (0·76–1·29)
426–525 326–425 5792 0·77 2·3% (1·7–2·9) 5898 314 91 1·12 (0·89–1·42) 1·12 (0·87–1·43)
401–500 301–400 6536 0·80 2·7% (2·0–3·4) 6874 366 126 1·04 (0·84–1·29) 1·09 (0·85–1·38) 
376–475 276–375 7029 0·84 2·8% (2·2–3·5) 7926 400 151 1·11 (0·91–1·37) 1·19 (0·96–1·47)
351–450 251–350 7433 0·84 3·2% (2·5–3·9) 8989 472 189 1·17 (0·97–1·41) 1·28 (1·04–1·57)
326–425 226–325 7775 0·86 3·3% (2·7–3·8) 10067 530 208 1·08 (0·90–1·28) 1·21 (1·01–1·46) 
301–400 201–300 8226 0·89 3·8% (3·1–4·5) 10980 584 258 1·15 (0·98–1·36) 1·34 (1·12–1·61)
276–375 176–275 8519 0·91 5·3% (4·3–6·3) 11 775 640 366 1·23 (1·05–1·44) 1·59 (1·30–1·95)
251–350 151–250 8748 0·92 6·1% (5·2–7·0) 12 104 719 412 1·30 (1·12–1·51) 1·71 (1·43–2·04)
226–325 126–225 8788 0·91 7·0% (6·2–7·8) 12 206 763 452 1·47 (1·27–1·70) 2·01 (1·73–2·35)
201–300 101–200 8878 0·92 8·1% (7·2–9·1) 11 976 822 485 1·59 (1·38–1·82) 2·21 (1·91–2·56)
176–275 76–175 8282 0·90 9·5% (8·6–10·4) 11 534 908 523 1·82 (1·60–2·08) 2·61 (2·27–3·00) 
151–250 51–150 7484 0·95 10·8% (9·9–11·7) 10 926 957 549 1·76 (1·55–2·01) 2·59 (2·29–2·92) 
126–225 26–125 6742 0·95 13·1% (12·1–14·1) 10 276 1088 642 2·01 (1·78–2·27) 2·88 (2·56–3·25) 
101–200 0–100 5871 0·92 17·6% (16·3–18·9) 10 014 1332 969 2·25 (2·01–2·51) 3·35 (2·99–3·75) 
CD4 cell count ranges have widths of 100 cells per μL, in increments of 25 cells per μL. Note that results in overlapping ranges are not statistically independent of each other. *Data for patients followed up in the 
era before the introduction of combination antiretroviral therapy. †Time from ﬁ rst CD4 cell count measurement in upper range to upper threshold of lower CD4 cell count range, AIDS, or death. ‡Hazard ratio 
based on analyses that ignored lead time and unseen AIDS and death events. 
Table 2: Hazard ratios for AIDS or death for deferral of combination antiretroviral therapy to a lower CD4 cell count range versus initiation at a higher CD4 cell count range 
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Figure 3: Adjusted hazard ratios for (A) AIDS or death and (B) death alone for initiation of combination antiretroviral therapy at a lower CD4 cell count 
threshold (ie, deferred initiation) versus initiation in a range up to 100 cells per μL higher
The horizontal axis shows the threshold values (upper limits of the CD4 cell count ranges in the deferred initiation groups [from 351–450 cells per μL, in steps of 
25 cells per μL, to 0–100 cells per μL]). See table 2 and table 3 for lists of hazard ratios and 95% CIs.
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351–450 cells per μL, by multiplying HRs for successive 
non-overlapping CD4 cell count ranges (251–350, 
151–250, and 51–150 cells per μL). 95% CIs for the 
plotted cumulative eﬀ ects were obtained by use of a 
Poisson approximation after decomposition of the 
variance into contributions from each of the CD4 cell 
count groups. All analyses were done with SAS version 9 
and Stata version 10.
Role of the funding source
The sponsor of the study had no role in the design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
21 247 AIDS-free patients with presumed transmission 
not by injecting drug use who were followed up during 
the era before the introduction of combination 
antiretroviral therapy (ie, between 1989 and 1995), and 
24 444 such patients from the ART Cohort Collaboration 
who were followed up from the start of combination 
therapy were included in the main analyses. 4159 (17%) 
patients were followed up for more than 6 years after the 
start of treatment (at which time follow-up data were 
censored because fewer than 20% of patients on 
combination therapy were followed for more than this 
length of time). Patient characteristics are shown in 
table 1. Compared with patients starting treatment, those 
followed up in 1989–95 were younger, more likely to be 
men who have sex with men, and more likely to develop 
AIDS or die during follow-up. We found little evidence 
that progression rates diﬀ ered between the earlier 
(1989–91) and later (1992–95) years of the era before 
combination therapy (webappendix p 11). The median 
annual decline in CD4 cell count during 1989–95 was 
60 cells per μL per year (95% CI 58–61). Among patients 
starting combination therapy, 9103 (37%) started treat-
ment with a CD4 cell count in the range 201–350 cells 
per μL, 5513 (23%) started in the range 101–200 cells per μL, 
and 5053 (21%) in the range 351–550 cells per μL. 
As reported previously,10,37 the cumulative probability of 
AIDS and death increased substantially with decreasing 
CD4 cell count at the time of treatment initiation 
(ﬁ gure 2). However, this ﬁ nding does not necessarily 
imply that treatment should be started before CD4 cell 
counts decline to the lower ranges, because this 
comparison does not account for lead time or unseen 
AIDS and death events (ﬁ gure 1).
Table 2 compares rates of progression to AIDS or death 
in adjacent CD4 cell count ranges of width 100 cells 
per μL. The median decline in CD4 cell count from the 
ﬁ rst measurement in the upper range to the upper 
threshold of the lower range varied from 48 cells per μL 
for upper range 451–550 cells per μL to 61 cells per μL for 
upper range 101–200 cells per μL. Estimated lead times 
increase with decreasing CD4 cell count. This ﬁ nding 
Higher CD4 cell 
count range 
(cells per μL)
Lower CD4 cell 
count range 
(cells per μL)
Data for 1989–95* Data for patients on combination 
antiretroviral therapy
Mortality hazard ratio (95% CI)
Number of 
patients in 
higher CD4 cell 
count range
Estimated 
median 
lead time 
(years)†
Estimated proportion of patients 
progressing to death before 
reaching upper threshold of lower 
CD4 cell count range (% [95% CI])
Number 
of patients
Number 
of deaths
Estimated 
number of 
unseen 
deaths
Naive‡ Adjusted for lead 
times and unseen 
deaths
451–550 351–450 5015 0·66 0·5% (0·3–0·7) 5053 92 15 1·06 (0·69–1·62) 0·93 (0·60–1·44)
426–525 326–425 5792 0·77 0·6% (0·3–1·0) 5910 108 26 1·03 (0·69–1·52) 0·96 (0·63–1·46)
401–500 301–400 6536 0·81 0·7% (0·4–0·9) 6887 129 29 1·15 (0·80–1·65) 1·01 (0·68–1·50)
376–475 276–375 7029 0·84 0·6% (0·4–0·9) 7943 149 30 1·20 (0·86–1·69) 0·99 (0·68–1·43)
351–450 251–350 7433 0·84 0·7% (0·4–1·1) 9013 183 41 1·38 (1·01–1·88) 1·13 (0·80–1·60)
326–425 226–325 7775 0·88 0·8% (0·5–1·1) 10 099 208 48 1·43 (1·07–1·91) 1·24 (0·92–1·67)
301–400 201–300 8226 0·87 1·0% (0·2–1·8) 11 021 239 67 1·43 (1·10–1·86) 1·25 (0·86–1·82)
276–375 176–275 8519 0·89 1·1% (0·8–1·5) 11 825 264 72 1·43 (1·12–1·84) 1·32 (0·98–1·78)
251–350 151–250 8748 0·92 1·4% (0·8–2·0) 12 159 294 90 1·32 (1·04–1·66) 1·23 (0·90–1·69)
226–325 126–225 8788 0·90 1·5% (0·9–2·1) 12 269 324 93 1·41 (1·13–1·76) 1·34 (1·01–1·77)
201–300 101–200 8878 0·92 1·6% (1·1–2·0) 12 051 348 84 1·44 (1·16–1·78) 1·34 (1·05–1·71)
176–275 76–175 8282 0·91 1·8% (1·6–2·1) 11 626 362 91 1·48 (1·21–1·82) 1·51 (1·21–1·87)
151–250 51–150 7484 0·93 2·2% (1·8–2·6) 11 044 369 104 1·48 (1·21–1·82) 1·61 (1·29–2·01)
126–225 26–125 6742 0·92 2·7% (2·2–3·1) 10 432 417 125 1·58 (1·30–1·91) 1·75 (1·43–2·15)
101–200 0–100 5871 0·89 3·7% (3·0–4·4) 10 248 500 184 1·73 (1·45–2·08) 2·04 (1·70–2·46)
CD4 cell count ranges have widths of 100 cells per μL, in increments of 25 cells per μL. *Data for patients followed up in the era before the introduction of combination antiretroviral therapy. †Time from ﬁ rst CD4 
cell count measurement in upper range to upper threshold of lower CD4 cell count range, AIDS, or death. ‡Hazard ratio based on analyses that ignored lead time and unseen AIDS and death events.
Table 3: Hazard ratios for death for deferral of combination antiretroviral therapy to a lower CD4 cell count range versus initiation at a higher CD4 cell count range
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occurs, in part, because the variability of CD4 cell counts 
is greater at higher ranges than at lower ranges; therefore, 
observed declines are more rapid. As expected, the 
estimated proportion of patients progressing to AIDS or 
death before reaching the upper threshold of the lower 
CD4 cell count range (the percentage of patients with 
unseen AIDS and death events) increases with decreasing 
CD4 cell count.
Table 2 also shows naive HRs and HRs adjusted for 
lead time and unseen events for AIDS and death for 
initiation of combination therapy that is deferred until a 
lower CD4 cell count range, compared with initiation of 
treatment at a higher CD4 cell count range. Adjustment 
for age at initiation, sex, and risk group (men who have 
sex with men versus other) did not substantially aﬀ ect 
naive HRs (webappendix p 11). Compared with initiation 
of treatment when CD4 cell count is in the range 
351–450 cells per μL, deferring treatment to 251–350 cells 
per μL leads to increased rates of AIDS or death (adjusted 
HR 1·28, 95% CI 1·04–1·57). At the higher CD4 cell 
count ranges, there was little evidence to suggest that 
deferred initiation of treatment was associated with 
higher rates of AIDS and death. The eﬀ ect of accounting 
for unseen AIDS and death events outweighs the eﬀ ect 
of lead time in comparisons of lower CD4 cell count 
ranges, so that adjusted HRs exceed naive HRs. By 
contrast, at higher CD4 cell counts, rates of unseen events 
are lower, and approximately balance the eﬀ ect of lead 
time, so that the naive and adjusted HRs are similar. 
Figure 3 shows the successive increase in rates of AIDS 
or death as combination therapy is deferred to lower 
CD4 cell count thresholds. 
Table 3 shows that, as expected, mortality rates increase 
with declining CD4 cell count. Compared with HRs for 
the combined endpoint of progression to AIDS and 
death, the HRs for mortality alone have wider 95% CIs, 
because the number of deaths is smaller than the number 
of combined AIDS and death events. Deferred initiation 
of combination therapy was associated with higher 
mortality rates, although eﬀ ects on mortality were less 
marked than eﬀ ects on AIDS and death. The mortality 
HR for deferred initiation of treatment at CD4 cell count 
251–350 cells per μL compared with initiation at 
351–450 cells per μL was 1·13 (0·80–1·60): there was little 
evidence that deferred initiation of treatment was 
associated with increased mortality rates in higher 
CD4 cell count ranges. The beneﬁ cial eﬀ ects of earlier 
initiation of treatment were greater in the ﬁ rst 2 years of 
follow-up than in the period from 2 to 6 years’ follow-up, 
apart from in the highest CD4 cell count ranges 
(webappendix p 12).
We repeated analyses in patients with presumed 
transmission by injecting drug use. In 4605 such patients 
receiving combination therapy, there were 653 AIDS or 
death events (334 deaths) during 15 141 years of follow-
up. In 9860 patients followed during 1989–95, there were 
905 AIDS or death events (823 deaths) during 27 182 years 
of follow-up. Estimated HRs for deferring start of 
treatment to lower CD4 cell count ranges compared with 
starting at higher ranges are shown in the webappendix 
(p 12). For comparisons in which the threshold CD4 cell 
count was low, the estimated beneﬁ ts of earlier initiation 
were lower for patients whose presumed transmission 
was by injecting drug use than for patients in the main 
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Figure 4: Hazard ratios for the cumulative eﬀ ect of deferred initiation of combination antiretroviral therapy for (A) AIDS or death and (B) death alone, 
compared with starting treatment at CD4 cell count range 351–450 cells per μL 
The horizontal axis shows the upper limits of the lower CD4 cell count range (251–350 cells per μL, 151–250 cells per μL, and 51–150 cells per μL).
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analyses. At higher CD4 cell count thresholds, the 
estimated beneﬁ ts of earlier initiation were generally 
consistent with those found in the main analyses, 
although as expected (given that the numbers of patients 
with transmission by injecting drug use were smaller 
than in the main analyses), 95% CIs were wide.
Four cohorts contributed data for patients receiving 
combination therapy (13 084 [54%] patients) as well as data 
for patients followed up during 1989–95 (17 993 [85%] 
patients). The results of sensitivity analyses for the 
combined AIDS and death endpoint, restricted to patients 
from these cohorts, were consistent with the main analyses 
(webappendix p 13). Most HRs for the adverse eﬀ ect of 
deferred treatment were larger than those for patients in 
the main analyses, particularly for low CD4 cell count 
ranges.
The webappendix (p 13) shows the results of sensitivity 
analyses in which distributions of lead times and unseen 
events were estimated on the assumption that treatment in 
the deferred initiation group was started at the ﬁ rst CD4 cell 
measurement in the lower range or, if there was no such 
measurement, at the midpoint of the range. The eﬀ ect of 
the resulting additional unseen events outweighed the 
eﬀ ect of the additional lead time, so that hazard ratios for 
the adverse eﬀ ect of deferring treatment on rates of AIDS 
and death generally increased.
Compared with start of treatment in the range 
351–450 cells per μL, deferred initiation of treatment at a 
CD4 cell count between 51 cells per μL and 150 cells per 
μL was associated with an HR of 5·67 (4·83–6·65) for the 
combined endpoint of AIDS and death, and an HR of 
2·24 (1·72–2·92) for mortality (ﬁ gure 4). In the ART 
Cohort Collaboration, 37% of patients started combination 
therapy with a CD4 cell count below 150 cells per μL.
Discussion
This collaborative analysis of data from over 45 000 patients 
who were followed up in cohort studies in Europe and 
North America suggests that in AIDS-free HIV-1-infected 
individuals, deferring the start of combination 
antiretroviral therapy until CD4 cell counts are in the 
range 251–350 cells per μL leads to increased rates of the 
combined endpoint of AIDS or death compared with 
starting in the range 351–450 cells per μL. As expected, 
the excess of AIDS or death associated with deferred 
initiation of combination therapy became more 
pronounced as the CD4 cell count threshold for starting 
treatment decreased. Eﬀ ects of deferring treatment on 
mortality alone were less pronounced, but patterns were 
consistent with those for rates of the combined endpoint 
of AIDS or death. Beneﬁ cial eﬀ ects of early initiation 
tended to be greater during the ﬁ rst 2 years of follow-up 
than in the period from 2 to 6 years’ follow-up.
By contrast with previous studies that have compared 
rates of progression to AIDS or death from the time of 
initiation of combination antiretroviral therapy,8–10 we 
accounted for the treatment-free time spent by patients 
when treatment is delayed, and for the events that occur 
before initiation of treatment in these patients. Thus, 
our analyses aimed to estimate the intervention eﬀ ects 
that would be seen in studies in which patients were 
allocated to either initiation of treatment in a higher CD4 
cell count range or delayed initiation until reaching a 
lower CD4 cell count range. Because of the large number 
of patients included in this collaborative study, our 
analyses had reasonable power to detect diﬀ erences in 
progression rates. By contrast, previous studies that 
compared mortality rates in patients with immediate 
initiation of treatment with rates in patients in whom 
treatment was deferred were limited by a small number 
of endpoints.38,39 The analysis of the HIV Outpatient 
Study showed that mortality was reduced by 39% in 
patients who started treatment with CD4 cell count 
350–500 cells per μL compared with patients who 
deferred treatment until after the CD4 cell count had 
fallen to below 350 per μL; however, this result did not 
reach conventional levels of statistical signiﬁ cance 
(p=0·17).38 Previous analyses that used the method 
described here to account for lead time and unseen 
AIDS and death events were also based on much smaller 
numbers of patients.12,40
Since we combined data for large numbers of patients 
in this analysis, we were able to compare narrow CD4 cell 
count strata, of width 100 cells per μL, with the aim of 
identifying CD4 cell count ranges within which earlier 
initiation has beneﬁ cial eﬀ ects on rates of AIDS and 
death. Had we compared wider CD4 cell count ranges, 
HRs might have increased, at the cost of reduced clinical 
relevance. For example, a comparison of initiation of 
treatment in the range 301–500 cells per μL with deferral 
to the range 101–300 cells per μL would compare some 
patients who started at 490 cells per μL with some patients 
who started at 110 cells per μL.
Patients who had an AIDS event before the start of 
combination therapy were excluded because they have 
worse prognosis and are likely to start treatment 
irrespective of their CD4 cell count.41 Nevertheless, our 
analyses included patients from many countries from 
Europe and North America who were treated in diﬀ erent 
settings. The range of patients was broad: men and women, 
patients aged from 16 years to 90 years, and patients 
presumed to have been infected through heterosexual sex 
as well as men who have sex with men. We analysed data 
from patients infected by injecting drug use separately, to 
avoid possible confounding because of comorbidities, 
deferred treatment, and non-adherence in these patients. 
HIV-infected intravenous drug users have a high prevalence 
of comorbidities13 and worse prognosis after combination 
antiretroviral therapy.14,15 Because our conclusions for this 
subgroup of patients were similar to those for all patients, 
our results should be applicable to many patients starting 
or considering combination therapy in developed countries. 
The clear disadvantages of delaying initiation of treatment 
until CD4 count is below 200 cells per μL might also have 
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implications for resource-limited settings, where eligibility 
criteria for initiation of combination artiretroviral therapy 
are often advanced immunodeﬁ ciency or clinical disease.42
An important assumption made in these analyses is 
that progression rates and mortality in the era before the 
introduction of combination antiretroviral therapy (ie, 
1989–95), are an appropriate reﬂ ection of what they 
would have been in the absence of this treatment in 
recent years. During the 1990s, the introduction of 
chemoprophylaxis, immunisation, and better strategies 
for the management of acute opportunistic infections 
contributed to prevention of clinical progression and 
improvement of survival rates in HIV-1-infected patients. 
In particular, the introduction of prophylaxis against 
Pneumocystis jirovecii pneumonia43 and against 
Mycobacterium avium complex disease in 199344 were 
important developments. Although substantially less 
eﬀ ective than combination antiretroviral therapy, 
monotherapy (mainly with zidovudine)45 became available 
in the late 1980s, and dual therapy with two nucleoside 
reverse transcriptase inhibitors46 became available during 
the mid-1990s. These factors will have acted in opposite 
directions: rates of AIDS and death in 1989–91 might 
have been higher than contemporary rates in the absence 
of treatment because of lower rates of prophylaxis, 
whereas rates in 1992–95 might have been reduced 
because some patients were treated with monotherapy or 
dual therapy. We suggest that biases introduced by these 
factors will have been limited. First, both prophylaxis and 
treatment were used mainly in patients with CD4 cell 
counts less than 200 cells per μL, in whom the adverse 
consequences of delayed initiation of treatment are clear. 
Second, monotherapy was of only limited, transient 
beneﬁ t,45 and dual therapy became widely available only 
during late 1994 and early 1995. Third, we found little 
evidence that rates of AIDS and death diﬀ ered between 
the earlier (1989–91) and later (1992–95) years of the era 
before combination anti retroviral therapy within the 
diﬀ erent CD4 cell count ranges. Some patients included 
in the dataset of patients receiving combination therapy 
had an initial regimen that included an unboosted rather 
than boosted protease inhibitor, which might have 
attenuated the beneﬁ cial eﬀ ect of treatment in the early 
portion of follow-up.47
As is the case for any observational study, our results 
might have been aﬀ ected by confounding and selection 
biases, if patient characteristics associated with deferred 
initiation of treatment are also predictive of progression 
rates on or oﬀ  therapy. We aimed to deal with such 
biases by excluding patient groups known to have 
higher progression rates. As well as excluding patients 
infected by injecting drug use and those who had an 
AIDS event before the start of combination therapy, we 
excluded patients who started treatment before 1998, 
when regimens were less eﬀ ective than those now 
available.48,49 Nonetheless, our results might still be 
aﬀ ected by unmeasured confounding factors. A 
randomised controlled trial would overcome such 
concerns; moreover, it could take into account factors 
outside the scope of our analysis, such as non-AIDS-
deﬁ ning events, severe and non-severe AIDS events, 
and drug-related toxic eﬀ ects. Therefore, a more 
deﬁ nitive answer to the question of when to start 
combination therapy will only be given when results 
become available from randomised controlled trials, 
such as the Strategic Timing of Antiretroviral Treatment 
(START) trial (registered with ClinicalTrials.gov, 
number NCT00821171). This study aims to establish 
whether immediate initiation of combination treatment 
is superior (in terms of morbidity and mortality) to 
deferral of treatment until the CD4 cell count falls 
below 350 cells per μL in HIV-1-infected people who are 
antiretroviral naive with a CD4 cell count greater than 
500 cells per μL.
In the absence of deﬁ nitive evidence from randomised 
controlled trials, it is necessary to rely on observational 
evidence when formulating guidelines on the CD4 cell 
count at which combination therapy should be started. 
When patients and their physicians consider starting 
antiretroviral treatment, they must balance its beneﬁ cial 
eﬀ ects on rates of progression to AIDS and death with 
several other issues.50,51 Eradication of HIV from an 
individual is not currently possible;52 therefore, treatment 
is expected to be lifelong. Antiretroviral drugs can be 
inconvenient to take, and have side-eﬀ ects that include 
nausea, diarrhoea, and headache. Combination anti-
retroviral therapy is associated with serious toxic eﬀ ects 
including lipodystrophy and lipoatrophy syndromes,53,54 
hepatitis, renal failure and mitochondrial toxicity,27 and 
an increased risk of cardiovascular disease.55 However, 
these toxic eﬀ ects are to an extent avoidable through 
choice of drug regimen: for example, increases in 
cardiovascular risk seem greater for protease inhibitors 
than for non-nucleoside reverse transcriptase inhibitors,56 
and lipoatrophy is associated with thymidine analogues.57 
Further, the HR of 1·28 for the comparison of deferring 
initiation of treatment to the CD4 cell count range 
251–350 cells per μL with initiation at 351–450 cells 
per μL represents only a small absolute diﬀ erence in the 
risk of AIDS or death over the follow-up period considered 
here.
Recent results from the SMART trial of structured 
treatment interruptions have also brought new 
perspectives to our understanding of the beneﬁ ts and 
risks of combination antiretroviral therapy.6 In that trial, 
patients who had started treatment at high CD4 cell 
counts and subsequently had treatment interrupted had 
higher rates not only of AIDS and death, but also of 
serious non-AIDS events such as myocardial infarction, 
stroke, liver cirrhosis, and renal failure. The analyses 
presented in this report do not account for non-fatal 
serious non-AIDS events, which might be the major 
causes of morbidity and subsequent mortality at higher 
CD4 cell counts. Non-AIDS deaths in untreated 
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individuals might account for the early high mortality 
HRs for deferred initiation compared with immediate 
initiation during the ﬁ rst 2 years of follow-up 
(webappendix p 12). Data from the EuroSIDA study show 
that rates of death from non-AIDS causes declined 
substantially at the start of the era of combination 
antiretroviral therapy.58,59
Thus, our ﬁ ndings should help to guide physicians 
and patients in deciding when to start antiretroviral 
treatment. The evolution of guidelines has been 
compared to the swings of a pendulum,60,61 from initial 
enthusiasm for early treatment,62 through to caution 
because of concern about toxic eﬀ ects and the risk of 
resistance and loss of treatment options,63 to more recent 
calls for earlier treatment.64 The International AIDS 
Society USA panel recommended in August, 2008, that 
antiretroviral therapy is started in individuals with CD4 
cell counts less than 350 cells per μL, and that this 
decision should be individualised when the CD4 cell 
count is greater than 350 cells per μL.65 Recent US66 and 
European guidelines make similar recommendations.67 
Because we found evidence that deferral of treatment 
until the patient’s CD4 cell count is less than 350 cells 
per μL was associated with increased progression rates, 
and in view of diminished concerns about toxic eﬀ ects 
and resistance,51,68 our results suggest that 350 cells per 
μL should be the minimum threshold at which 
antiretroviral therapy is started.
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